US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Key Highlights:
- US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company
- Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of negotiations with study centres and receipt of relevant...
Read more: US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD